Equities Analysts Offer Predictions for ATRA Q3 Earnings

Key Points

• HC Wainwright estimates that Atara Biotherapeutics will report a Q3 2025 earnings per share of ($0.83), while the current consensus for the full year stands at ($10.39) EPS.
• Atara Biotherapeutics recently reported a better-than-expected earnings result, with $0.19 EPS for the last quarter, exceeding the consensus estimate by $0.51.
• Insider activity saw Innovation Ltd Panacea acquiring 55,000 shares of Atara Biotherapeutics, increasing their ownership by 4.07%.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report) - Stock analysts at HC Wainwright issued their Q3 2025 earnings estimates for shares of Atara Biotherapeutics in a research note issued to investors on Tuesday, August 19th. HC Wainwright analyst R. Burns expects that the biotechnology company will earn ($0.83) per share for the quarter. The consensus estimate for Atara Biotherapeutics' current full-year earnings is ($10.39) per share. HC Wainwright also issued estimates for Atara Biotherapeutics' Q4 2025 earnings at ($0.68) EPS, FY2025 earnings at $1.72 EPS and FY2026 earnings at $0.87 EPS.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last released its earnings results on Monday, August 11th. The biotechnology company reported $0.19 EPS for the quarter, beating the consensus estimate of ($0.32) by $0.51. Atara Biotherapeutics had a net margin of 3.07% and a negative return on equity of 8.34%. The company had revenue of $17.58 million for the quarter, compared to analyst estimates of $4.23 million.

Atara Biotherapeutics Price Performance

ATRA traded up $0.85 during trading on Thursday, hitting $12.34. 90,718 shares of the stock traded hands, compared to its average volume of 50,828. The firm has a market capitalization of $86.66 million, a P/E ratio of -28.70 and a beta of 0.26. The firm has a 50-day moving average of $10.10 and a 200 day moving average of $8.23. Atara Biotherapeutics has a 12-month low of $5.01 and a 12-month high of $18.70.

Insider Buying and Selling at Atara Biotherapeutics

In related news, major shareholder Innovation Ltd Panacea bought 55,000 shares of the business's stock in a transaction dated Friday, August 15th. The shares were purchased at an average price of $12.19 per share, with a total value of $670,450.00. Following the purchase, the insider owned 1,405,000 shares of the company's stock, valued at approximately $17,126,950. This trade represents a 4.07% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.00% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in Atara Biotherapeutics by 2.5% in the second quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company's stock worth $464,000 after buying an additional 1,457 shares during the last quarter. Bank of America Corp DE grew its position in Atara Biotherapeutics by 0.8% during the fourth quarter. Bank of America Corp DE now owns 205,170 shares of the biotechnology company's stock valued at $2,731,000 after buying an additional 1,543 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in Atara Biotherapeutics during the fourth quarter valued at approximately $48,000. Raymond James Financial Inc. bought a new position in shares of Atara Biotherapeutics in the second quarter worth approximately $31,000. Finally, Citadel Advisors LLC boosted its position in shares of Atara Biotherapeutics by 2.6% in the fourth quarter. Citadel Advisors LLC now owns 267,353 shares of the biotechnology company's stock worth $3,558,000 after purchasing an additional 6,873 shares during the period. 70.90% of the stock is owned by hedge funds and other institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.